Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Strategy & Legal Officer | August 01, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 205,968 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Tax withholding · Disposed 4,699 · Balance 205,968 F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 19, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,900 | $19.50 | $95,550.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · derivative · entry 6 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,541 Underlying: Common Stock · 100 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 11,100 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $50.00 | $5,000.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 18, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 100 | $19.50 | $1,950.00 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 30, 2019 Filed Jul 22, 2019 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 52 | $36.83 | $1,915.16 |
DisclosureSEC source: 0001562180-19-004025 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,058 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2019 through June 30, 2019. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2019. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-19-003602 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,931 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $54.75 | $5,475.00 |
DisclosureSEC source: 0001562180-19-003602 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,006 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,934 | $53.29 | $103,062.86 |
DisclosureSEC source: 0001562180-19-003602 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,106 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.98 to $53.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,966 | $52.74 | $156,426.84 |
DisclosureSEC source: 0001562180-19-003602 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,040 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $51.96 to $52.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-19-003602 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,459 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · derivative · entry 8 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,641 Underlying: Common Stock · 1,459 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 11,100 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 4, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,541 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · derivative · entry 7 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,931 Underlying: Common Stock · 3,541 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $55.50 | $5,550.00 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 6 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,006 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 885 | $54.66 | $48,374.10 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,106 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $54.32 to $55.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,115 | $53.67 | $59,842.05 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,991 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $53.20 to $54.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,900 | $52.55 | $152,395.00 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,106 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $52.12 to $53.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,459 | $19.50 | $28,450.50 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 3,541 | $12.10 | $42,846.10 |
DisclosureSEC source: 0001562180-19-002324 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $40.82 | $0.00 |
DisclosureSEC source: 0001562180-19-000222 · primarydocument.xml · derivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 31, 2018 Filed Jan 7, 2019 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 337 | $35.66 | $12,016.58 |
DisclosureSEC source: 0001562180-19-000222 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,006 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2018 through December 31, 2018. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2018. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-005060 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,472 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 720 | $48.97 | $35,258.40 |
DisclosureSEC source: 0001562180-18-005060 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.77 to $49.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,055 | $47.85 | $98,331.75 |
DisclosureSEC source: 0001562180-18-005060 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,389 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.54 to $48.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,225 | $46.79 | $104,107.75 |
DisclosureSEC source: 0001562180-18-005060 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,444 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.21 to $47.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:27 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-18-005060 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,000 | $72.06 | $1,080,900.00 |
DisclosureSEC source: 0001562180-18-004476 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.00 to $72.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,472 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 90 | $62.67 | $5,640.30 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,410 | $62.00 | $211,420.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.65 to $62.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,500 | $61.22 | $91,830.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.63 to $61.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-18-004259 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-003744 · primarydocument.xml · derivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,472 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,600 | $66.41 | $106,256.00 |
DisclosureSEC source: 0001562180-18-003744 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,669 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $66.20 to $66.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,400 | $65.75 | $223,550.00 |
DisclosureSEC source: 0001562180-18-003744 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,269 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $65.15 to $66.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:15 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-18-003744 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,528 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · derivative · entry 6 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,472 Underlying: Common Stock · 1,528 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,528 | $12.10 | $18,488.80 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 5,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,600 | $56.91 | $261,786.00 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.35 to $57.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 400 | $55.25 | $22,100.00 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,741 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $55.15 to $55.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $12.10 | $60,500.00 |
DisclosureSEC source: 0001562180-18-003069 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · derivative · entry 6 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 15,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| May 10, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $12.10 | $181,500.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · nonDerivative · entry 4 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · derivative · entry 5 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 15,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,000 | $44.00 | $440,000.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · nonDerivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,000 | $42.00 | $210,000.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $12.10 | $181,500.00 |
DisclosureSEC source: 0001562180-18-002457 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001562180-18-001892 · primarydocument.xml · derivative · entry 3 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 10,000 shares Expires 2026-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,000 | $39.00 | $390,000.00 |
DisclosureSEC source: 0001562180-18-001892 · primarydocument.xml · nonDerivative · entry 2 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 11, 2018 Filed Apr 13, 2018 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 10,000 | $12.10 | $121,000.00 |
DisclosureSEC source: 0001562180-18-001892 · primarydocument.xml · nonDerivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.